|
ARB 304
|
ARB 305
|
ARB 336
|
ARB 354
|
ARB 355
|
SESSION 1
1:20 – 2:05 pm
|
Alex Metzger, Pharm.D
Management of Linezolid with Concomitant Serotonergic Agents
|
Cody Craven, Pharm.D
Administration of Intravenous Magnesium Sulfate for Atrial Fibrillation with Rapid Ventricular Rate in the Emergency Department
|
Amber Laurent, Pharm.D
Precision Medicine in Pediatric Oncology
|
Jamie Voigtmann, Pharm.D
Are Shorter Courses of Antibiotic Better?
|
Janki Patel, Pharm.D
Duration of dual antiplatelet therapy post PCI: How short can we go?
|
2:05 – 2:15 pm
|
Travel Time to accommodate movement between rooms
|
||||
SESSION 2
2:15 – 3:00 pm
|
Kyle Lyons, Pharm.D
Safe and Effective Use of Methadone in Pain Management
|
Mikaela Hofer, Pharm.D
Future of Vasopressor Therapy
|
Allison Wicker, Pharm.D
Does an Aspirin a Day Keep Blood Clots Away after Orthopedic Surgery?
|
Sarah Mooney, Pharm.D
Emerging Treatment Options in Pediatric Patients with Type 2 Diabetes
|
Brooke Lucas, Pharm.D
Administration of tPA Following Idarucizumab Reversal of Dabigatran
|
3:00 – 3:10 pm
|
Travel Time to accommodate movement between rooms
|
||||
SESSION 3
3:10 – 3:55 pm
|
Evan Strake, Pharm.D
Sativex - Cannabinoids derivative for MS symptom management
|
Julia Wu, Pharm.D
Reflect Before You Rx: Inpatient Treatment of Asymptomatic Hypertension
|
Karli Kurwicki, Pharm.D
Graft-versus-host disease in Solid Organ Transplant
|
Lourdes Vega, Pharm.D
Assessing care plans for patients with type 2 diabetes practicing religious and cultural fasting
|
Lindsey Eble, Pharm.D
Oral Anticoagulant Use in Patients with Moderate to Severe Liver Impairment
|
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 2.25 contact hours. Participants must sign in AND complete an evaluation to receive credit.
Click here for a printable copy of the schedule
Registration is free, but is required in advance. Due to limited space, only those participants who register before 12:00 PM on Wednesday, October 30, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or by clicking here », to complete your parking request. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website. Sessions you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block. To do so, participants must complete an online evaluation for those sessions attended no later than two weeks following the sessions. Participants must be logged on and registered in order to view and complete the evaluation(s). Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign in sheets, the offending participant forfeits CE credit.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify us in advance so that we may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Nov 8, 2019 01:20 AM - 04:45 AM
Fee
CE Hours
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
The overall goal for this lecture is first to be able to understand the difference between serotonin syndrome and other neurological disorders, and then to know how to manage patients on linezolid and other serotonergic agents.
Speaker(s)/Author(s)
Alex Metzger, Pharm.D. |
Activity Number
0033-0000-19-113-L01-PCE Hours
Location
Speaker(s)/Author(s)
Cody Craven, Pharm.D. |
Activity Number
0033-0000-19-109-L01-PCE Hours
Location
Speaker(s)/Author(s)
Amber Laurent, Pharm.D. |
Activity Number
0033-0000-19-112-L01-PCE Hours
Location
Current literature suggests that shorter courses of antibiotics for soft tissue infections, uncomplicated cystitis, pyelonephritis, and uncomplicated gram-negative bacteremia are non-inferior to longer, traditional courses of therapy. This is important to consider because antibiotic resistance is quickly increasing. Additionally, there are many benefits to shorter courses of antibiotics such as decreased healthcare costs, decreased length of hospital stay, and decreased adverse effects. Many studies have determined that in the hospital, broad-spectrum antibiotics are used for extended durations based on clinician preferences rather than guidelines. Other infections, such as gram negative bacteremia do not have guidelines to follow, and lack clinical evidence to support an appropriate duration of therapy. Overall, pharmacists should be stewards of antibiotics and ensure patients are getting the appropriate regimens with the correct durations of therapy. The objective of this presentation is to recognize patients that are good candidates for short course antibiotics.
Speaker(s)/Author(s)
Jamie Voigtmann, Pharm.D. |
Activity Number
0033-0000-19-117-L01-PCE Hours
Location
Speaker(s)/Author(s)
Janki Patel, Pharm.D. |
Activity Number
0033-0000-19-106-L01-PCE Hours
Location
Speaker(s)/Author(s)
Kyle Lyons, Pharm.D. |
Activity Number
0033-0000-19-108-L01-PCE Hours
Location
Speaker(s)/Author(s)
Mikaela Hofer, Pharm.D. |
Activity Number
0033-0000-19-111-L01-PCE Hours
Location
Venous thromboembolism (VTE) is a well-known complication following orthopedic surgery. With various strategies for VTE prophylaxis recommended by current guidelines, the optimal strategy to minimize the risk of VTE as well as bleeding is unknown. This program will review the options for VTE prophylaxis following orthopedic surgery with a focus on the efficacy of aspirin in this patient population. While aspirin is a favorable option due to cost-effectiveness and wide availability, does it effectively reduce the risk of VTE as compared to standard anticoagulant therapy?
Speaker(s)/Author(s)
Allison Wicker, Pharm.D. |
Activity Number
0033-0000-19-115-L01-PCE Hours
Location
The incidence of type 2 diabetes mellitus in the American pediatric population increased in the early 2000s and is projected to continue increasing over the next few decades. The FDA-approved treatment options for pediatric patients with type 2 diabetes have historically been limited to metformin and insulin. Metformin is the first-line option for pediatric and adult patients with type 2 diabetes; however, metformin and insulin have not shown the same efficacy in the pediatric population that is demonstrated in adults with the disease. The ELLIPSE Trial investigated the efficacy and safety of the use of subcutaneous liraglutide in children and adolescents with type 2 diabetes who were already on metformin with or without basal insulin therapy. This presentation will discuss the results of the ELLIPSE study, highlight other treatment options currently under investigation, and provide a review of type two diabetes mellitus in children and adolescents. The results of the ELLIPSE trial and emerging treatment options have the potential to make significant impact on children and adolescents with type 2 diabetes who struggle to achieve control of their disease.
Speaker(s)/Author(s)
Sarah Mooney, Pharm.D. |
Activity Number
0033-0000-19-105-L01-PCE Hours
Location
Speaker(s)/Author(s)
Brooke Lucas, Pharm.D. |
Activity Number
0033-0000-19-107-L01-PCE Hours
Location
Speaker(s)/Author(s)
Evan Strake, Pharm.D. |
Activity Number
0033-0000-19-119-L01-PCE Hours
Location
Speaker(s)/Author(s)
Julia Wu, Pharm.D. |
Activity Number
0033-0000-19-116-L01-PCE Hours
Location
Speaker(s)/Author(s)
Karli Kurwicki, Pharm.D. |
Activity Number
0033-0000-19-114-L01-PCE Hours
Location
Speaker(s)/Author(s)
Lourdes Vega, Pharm.D. |
Activity Number
0033-0000-19-118-L01-PCE Hours
Location
Speaker(s)/Author(s)
Lindsey Eble, Pharm.D. |